131I therapy for 345 patients with refractory severe hyperthyroidism: Without antithyroid drug pretreatment

• Published in: Experimental biology and medicine (Maywood, N.J.) N.J.), 2016-02, Vol.241 (3), p.290-295
• Main Authors: Ding, Yong, Xing, Jialiu, Fang, Yi, Wang, Yong, Zhang, Youren, Long, Yahong
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antithyroid Agents - administration & dosage; Drug-Related Side Effects and Adverse Reactions - epidemiology; Female; Follow-Up Studies; Humans; Hyperthyroidism - radiotherapy; Iodine Radioisotopes - administration & dosage; Iodine Radioisotopes - adverse effects; Male; Middle Aged; Original Research; Thyroid Gland - diagnostic imaging; Thyroid Gland - pathology; Thyroid Gland - physiology; Treatment Outcome; Ultrasonography; Young Adult
• ISSN: 1535-3702; 1535-3699
• DOI: 10.1177/1535370215602784

The aim of this study is to evaluate the safety and long-term results of 131I therapy alone for patients with refractory severe hyperthyroidism without antithyroid drug pretreatment. From January 2002 to December 2012, 408 patients with refractory severe hyperthyroidism were treated with 131I alone. Among them, 345 were followed up for 1 to 10 years for physical examination, thyroid function, and thyroid ultrasound. Complete Blood Count (CBC) liver function, electrocardiogram, echocardiogram, and Emission Computed Tomography (ECT) thyroid imaging were performed as indicated. The 345 patients had concomitant conditions including thyrotoxic heart disease, severe liver dysfunction, enlarged thyroid weighing 80 to 400 g, severe cytopenia, and vasculitis. One to two weeks prior to 131I therapy, all patients were given low-iodine diet. The dose of 131I therapy was 2.59 to 6.66 MBq (70 to180 µCi) per gram of thyroid with an average of 3.83 ± 0.6 MBq (103.6 ± 16.4 µCi); and the total 131I activity administrated for the individuals was 111 to 3507.6 MBq (3.0 to 94.8 mCi, mean 444 ± 336.7 MBq (12.0 ± 9.1 mCi)). Out of the 408 patients, 283 were cured, 15 with complete remission, and 47 with incomplete remission. No treatment failure or significant clinical worsening was noted in these patients. Our data indicated that 131I therapy alone for patients with refractory severe hyperthyroidism without antithyroid drug pretreatment is safe and effective.